medigraphic.com
ISSN 2954-3835 (Digital)
ISSN 2683-2828 (Impreso)

2023, Número 2

<< Anterior

Cardiovasc Metab Sci 2023; 34 (2)


Fibrilación auricular y obesidad: dos enfermedades epidémicas con interacciones complejas

Álvarez CJ, Asensio-Lafuente E, De CE, Rodríguez-Diez G

Idioma: Inglés [English version]
Referencias bibliográficas: 29
Paginas: 72-75
Archivo PDF: 194.13 Kb.


RESUMEN

La fibrilación auricular (FA) es una enfermedad crónica compleja, degenerativa y multifactorial cuya prevalencia e incidencia aumentan, de modo que puede considerarse una verdadera epidemia, como ocurre con la obesidad. La combinación de ambas enfermedades supone un mayor riesgo de morbilidad y mortalidad. La obesidad por sí misma es un factor de riesgo para la FA y se asocia con una peor evolución de esta compleja arritmia. En el presente trabajo, se revisan las interacciones fisiopatológicas entre obesidad y FA, así como los efectos positivos del control de la obesidad en la FA y la obtención de mejores resultados con las terapias disponibles en la actualidad para la arritmia.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Hindricks G, Potpara T, Dagres N et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J. 2021; 42 (5): 373-498. doi: 10.1093/eurheartj/ehaa612.

  2. Lavie CJ, Pandey A, Lau DH et al. Obesity and atrial fibrillation prevalence, pathogenesis, and prognosis: effects of weight loss and exercise. J Am Coll Cardiol. 2017; 70 (16): 2022-2035. doi: 10.1016/j.jacc.2017.09.002.

  3. Wang TJ, Parise H, Levy D et al. Obesity and the risk of new-onset atrial fibrillation. JAMA. 2004; 292 (20): 2471-2477. doi: 10.1001/jama.292.20.2471.

  4. Nalliah CJ, Sanders P, Kottkamp H, Kalman JM. The role of obesity in atrial fibrillation. Eur Heart J. 2016; 37 (20): 1565-1572. doi: 10.1093/eurheartj/ehv486.

  5. Mehra R, Benjamin EJ, Shahar E et al. Association of nocturnal arrhythmias with sleep-disordered breathing: The Sleep Heart Health Study. Am J Respir Crit Care Med. 2006; 173: 910-916. doi: 10.1164/rccm.200509-1442OC.

  6. Vyas V, Lambiase P. Obesity and atrial fibrillation: epidemiology, pathophysiology and novel therapeutic opportunities. Arrhythm Electrophysiol Rev. 2019; 8 (1): 28-36. doi: 10.15420/aer.2018.76.2.

  7. Javed S, Gupta D, Lip GYH. Obesity and atrial fibrillation: making inroads through fat. Eur Heart J Cardiovasc Pharmacother. 2021; 7 (1): 59-67. doi: 10.1093/ehjcvp/pvaa013.

  8. Goudis CA, Korantzopoulos P, Ntalas IV et al. Obesity and atrial fibrillation: a comprehensive review of the pathophysiological mechanisms and links. J Cardiol. 2015; 66 (5): 361-369. doi: 10.1016/j.jjcc.2015.04.002.

  9. Nakamura K, Fuster JJ, Walsh K. Adipokines: a link between obesity and cardiovascular disease. J Cardiol. 2014; 63: 250-259.

  10. Salska A, Dziuba M, Salski W et al. Apelin and atrial fibrillation: the role in the arrhythmia recurrence prognosis. Dis Markers. 2018; 2018: 5285392.

  11. Kaplon-Ciéslika A, Postula M, Rosiak M et al. Association between adipokines and inflammatory markers with lipid control in type 2 diabetes. Pol Arch Med Wewn. 2015; 125 (6): 414-423.

  12. Bohm A, Snopek P, Tothova L et al. Association between apelin and atrial fibrillation in patients with high risk of ischemic stroke. Front Cardiovasc Med. 2021; 8: 742601.

  13. Chen D, Zhang Y, Yidilisi A et al. Causal associations between circulating adipokines and cardiovascular disease: A mendelian randomization study. J Clin Endocrinol Metab. 2022; 107: e2572-e2580.

  14. Karam BS, Chávez-Moreno A, Koh W et al. Oxidative stress and inflammation as central mediators of atrial fibrillation in obesity and diabetes. Cardiovasc Diabetol. 2017; 16: 120-128.

  15. Mocini D, Di Fusco SA, Mocini E et al. Direct oral anticoagulants in patients with obesity and atrial fibrillation: position paper of Italian National Association of Hospital Cardiologists (ANMCO). J Clin Med. 2021; 10 (18): 4185. doi: 10.3390/jcm10184185. PMID: 34575306.

  16. Proietti M, Guiducci E, Cheli P, Lip GY. Is there an obesity paradox for outcomes in atrial fibrillation? A systematic review and meta-analysis of non-vitamin K antagonist oral anticoagulant trials. Stroke. 2017; 48: 857-866. doi: 10.1161/STROKEAHA.116.015984.

  17. Martin K, Beyer-Westendorf J, Davidson BL et al. Use of the direct oral anticoagulants in obese patients: guidance from the SSC of the ISTH. J Thromb Haemost. 2016; 14 (6): 1308-1313. doi: 10.1111/jth.13323.

  18. Thangjui S, Kewcharoen J, Yodsuwan R et al. Efficacy and safety of direct oral anticoagulant in morbidly obese patients with atrial fibrillation: systematic review and meta-analysis. Eur Heart J Cardiovasc Pharmacother. 2022; 8 (4): 325-335. doi: 10.1093/ehjcvp/pvab026.

  19. Shaikh F, Wynne R, Castelino RL et al. Effectiveness of direct oral anticoagulants in obese adults with atrial fibrillation: a systematic review of systematic reviews and meta-analysis. Front Cardiovasc Med. 2021; 8: 732828. doi: 10.3389/fcvm.2021.732828.

  20. Kaplan RM, Tanaka Y, Passman RS et al. Efficacy and safety of direct oral anticoagulants for atrial fibrillation across body mass index categories. J Am Heart Assoc. 2020; 9 (24): e017383. doi: 10.1161/JAHA.120.017383.

  21. Mhanna M, Beran A, Al-Abdouh A et al. Efficacy and safety of direct oral anticoagulants in morbidly obese patients with non-valvular atrial fibrillation: a systematic review and meta-analysis. Eur Heart J. 2021; 42: ehab724.3424. doi: 10.1093/eurheartj/ehab724.3424.

  22. Brar T, Chua D. Direct-acting oral anticoagulant choice for stroke prevention in obese patients with atrial fibrillation. Can J Cardiol. 2021; 37 (9): 1489-1492. doi: 10.1016/j.cjca.2021.04.004.

  23. Briasulis A, Mentias A, Mazur A et al. Comparative effectiveness and safety of direct oral anticoagulants in obese patients with atrial fibrillation. Cardiovasc Drugs Ther. 2021; 35 (2): 261-272. doi: 10.1007/s10557-020-07126-2.

  24. Boivin-Proulx LA, Potter BJ, Dorais M, Perreault S. Comparative effectiveness and safety of direct oral anticoagulants vs warfarin among obese patients with atrial fibrillation. CJC Open. 2022; 4 (4): 395-405. doi: 10.1016/j.cjco.2022.01.002.

  25. January CT, Wann LS, Calkins H et al. 2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2019; 74 (1): 104-132.

  26. Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 9 Jul 2019;74(1):104-132. doi: 10.1016/j.jacc.2019.01.011. PMID: 30703431

  27. Abed HS, Wittert GA, Leong DP et al. Effect of weight reduction and cardiometabolic risk factor management on symptom burden and severity in patients with atrial fibrillation: a randomized clinical trial. JAMA. 2013; 310 (19): 2050-2060. doi: 10.1001/jama.2013.280521.

  28. Pathak RK, Middeldorp ME, Meredith M et al. Long-term effect of goal-directed weight management in an atrial fibrillation cohort: a long-term follow-up study (LEGACY). J Am Coll Cardiol. 2015; 65 (20): 2159-2169. doi: 10.1016/j.jacc.2015.03.002.

  29. Middeldorp ME, Pathak RK, Meredith M et al. PREVEntion and regReSsive Effect of weight-loss and risk factor modification on Atrial Fibrillation: the REVERSE-AF study. Europace. 2018; 20 (12): 1929-1935. doi: 10.1093/europace/euy117.




2020     |     www.medigraphic.com